BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16331250)

  • 1. Involvement of Bcl-X(L) deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells.
    Chang CY; Lin YM; Lee WP; Hsu HH; Chen EI
    Oncogene; 2006 Apr; 25(18):2656-65. PubMed ID: 16331250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation.
    Shao R; Lee DF; Wen Y; Ding Y; Xia W; Ping B; Yagita H; Spohn B; Hung MC
    Mol Cancer Res; 2005 Apr; 3(4):219-26. PubMed ID: 15831675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.
    Dodier P; Piché A
    Gynecol Oncol; 2006 Feb; 100(2):254-63. PubMed ID: 16188300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
    Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
    Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between cytochrome c-mediated caspase-3 activity and chemoresistance in cisplatin-resistant human ovarian cancer cell lines].
    Yang X; Zheng F; Xing H; Gao Q; Wang W; Lu Y; Wang S; Ma D
    Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):544-7. PubMed ID: 12667321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis.
    Jiang M; Wei Q; Wang J; Du Q; Yu J; Zhang L; Dong Z
    Oncogene; 2006 Jul; 25(29):4056-66. PubMed ID: 16491117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism.
    Brader KR; Wolf JK; Hung MC; Yu D; Crispens MA; van Golen KL; Price JE
    Clin Cancer Res; 1997 Nov; 3(11):2017-24. PubMed ID: 9815592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model.
    Bartholomeusz C; Itamochi H; Yuan LX; Esteva FJ; Wood CG; Terakawa N; Hung MC; Ueno NT
    Cancer Res; 2005 Sep; 65(18):8406-13. PubMed ID: 16166319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NH(2)-terminal and conserved region 2 domains of adenovirus E1A mediate two distinct mechanisms of tumor suppression.
    Deng J; Kloosterbooer F; Xia W; Hung MC
    Cancer Res; 2002 Jan; 62(2):346-50. PubMed ID: 11809676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
    Sugimoto T; Bartholomeusz C; Tari AM; Ueno NT
    Breast Cancer Res; 2007; 9(4):R41. PubMed ID: 17612393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to fas-induced apoptosis in cells from human atherosclerotic lesions: elevated Bcl-XL inhibits apoptosis and caspase activation.
    Yang Z; Gagarin D; Ramezani A; Hawley RG; McCaffrey TA
    J Vasc Res; 2007; 44(6):483-94. PubMed ID: 17657164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of deamidation of Bcl-xL and translocation of Bax to the mitochondria through activation of JNK in the induction of apoptosis by treatment with GSH-conjugated DXR.
    Asakura T; Maeda K; Omi H; Matsudaira H; Ohkawa K
    Int J Oncol; 2008 Aug; 33(2):389-95. PubMed ID: 18636161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation.
    Kutuk O; Arisan ED; Tezil T; Shoshan MC; Basaga H
    Carcinogenesis; 2009 Sep; 30(9):1517-27. PubMed ID: 19578044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
    Brenes O; Arce F; Gätjens-Boniche O; Díaz C
    Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo.
    Deng J; Xia W; Hung MC
    Oncogene; 1998 Oct; 17(17):2167-75. PubMed ID: 9811448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis.
    Wang P; Song JH; Song DK; Zhang J; Hao C
    Cell Signal; 2006 Sep; 18(9):1528-35. PubMed ID: 16442262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of Bcl-xL deamidation in human hepatocellular carcinomas.
    Takehara T; Takahashi H
    Cancer Res; 2003 Jun; 63(12):3054-7. PubMed ID: 12810626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.